CN105596495A - Chinese herbal compound for treating pubertal polycystic ovary syndrome - Google Patents
Chinese herbal compound for treating pubertal polycystic ovary syndrome Download PDFInfo
- Publication number
- CN105596495A CN105596495A CN201610005069.2A CN201610005069A CN105596495A CN 105596495 A CN105596495 A CN 105596495A CN 201610005069 A CN201610005069 A CN 201610005069A CN 105596495 A CN105596495 A CN 105596495A
- Authority
- CN
- China
- Prior art keywords
- parts
- polycystic ovary
- ovary syndrome
- chinese herbal
- pubertal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
Abstract
The invention provides a Chinese herbal compound for treating the pubertal polycystic ovary syndrome. The Chinese herbal compound is prepared from, by weight, 30-35 parts of radix astragali, 20-25 parts of American ginseng, 15-20 parts of Radix Salviae Miltiorrhizae,, 15-20 parts of hawthorn, 15-20 parts of poria cocos, 20-25 parts of bighead atractylodes rhizome and 15-20 parts of tangerine peel. The pubertal polycystic ovary syndrome (PCOS) is treated through the method of tonifying qi and spleens, reducing phlegm, activating blood and regulating constitution; compared with other traditional Chinese medicine research, the Chinese herbal compound can reduce levels of luteinizing hormone (LH), luteinizing hormone/follicle-stimulating hormone (LH/FSH), testosterone (T) and androstenedione (AND) in serum of patients and also can reduce the levels of total cholesterol (TC) and apolipoprotein B (APOB) in blood fat, and therefore the aims of regulating the menstrual cycle, improving hyperandrogenism and correcting dyslipidemia are achieved.
Description
Technical field
The present invention relates to a kind of Chinese medicine compound prescription for the treatment of Polycystic Ovary Syndrome in Adolescence.
Background technology
Stein-Leventhal syndrome is the common endocrine system disease of Women of Childbearing Age, and the incidence of disease is 6%-15%, starts from puberty.In recent years puberty PCOS incidence increase gradually, be more and more subject to clinician's attention. Due to hebetic physiology spyPoint is overlapping with PCOS sings and symptoms, and the relevant common recognition of PCOS and guide recommendation PCOS diagnostic criteria in puberty must meet deerSpecial red three diagnostic criteria menstrual onset are more than 2 years: 1. oligomenorrhea, amenorrhoea or primary amenorrhea 2 after menarcheMore than year; 2. excessive androgen mass formed by blood stasis and Hyperandrogenism clinical manifestation; 3. abdominal ultrasonic performance: Ovarian Volume is necessary > 10cm3，Ovarian follicle >=12 of one side or bilateral ovaries diameter 2-9mm. At present puberty PCOS etiology undetermined, the main and youthBefore phase or Adolescent Obesity, menstrual onset too early, inherent cause, low birth weight, Premature adrenarche,Vitamin D deficiency, puberty, PCOS grew hyperfunction theory, antenatal Hyperandrogenism and long term exposure in bisphenol-A environmentDeng relevant. Puberty, PCOS pathogenesis complexity, can not be a kind of result of factor effect. The pathogenesis that it is mainRelate to the abnormal and genetic mechanism of insulin resistance, adipocyte dysfunction, hypothalamic-pituitary-ovarian axis more. Its treatmentBe mainly life style adjustment, symptomatic treatment and control Abnormality of Glycolipid Metabolism, conventional medicine is melbine and oral keeping awayPregnant medicine.
Stein-Leventhal syndrome is a kind of disease relevant to life style, and life style adjustment is the basis for the treatment of PCOS.Life style treatment comprises diet, motion, behaviour therapy three aspects:. Existing multinomial studies show that overweight and obesityPerson alleviates or controls body weight and can reduce the generation of periphery fat, reduces insulin resistance, suppresses the generation of ovarian androgens, entersAnd improve paramenia, excessive androgen mass formed by blood stasis, Abnormality of Glycolipid Metabolism and insulin resistance, but puberty PCOS patient inThe Development in Puberty stage, lose weight too fast can affect normal growth growth, and its many places are in junior middle school or senior high school period,Learning pressure is larger, can not ensure to keep on a diet fully and increase run duration to lose weight. Puberty, PCOS suffered fromPerson's medication need be selected medication according to patient's E&M abnormal conditions. Oral contraceptive is improving paramenia, heightThe aspects such as androgen mass formed by blood stasis, crinosity and acne have gained public acceptance, increase but bibliographical information Long-term Oral contraceptive can cause body weightAdd, swollen breasts, mood change, VTE, abnormal liver function and adrenal insufficiency etc. Part contraceptiveTo fat, metabolism has harmful effect, increases the level of triglycerides. Therefore when, research is pointed out to select oral contraceptive, note prisonSurvey the variation of blood sugar, blood fat, should do sufficient informed consent for Pubertal girls. A research is observed contraceptive to fertilizerThe effect of fat type PCOS in puberty, after treatment, the total testosterone of patient's serum and free AI obviously decline, but it is to bloodFat improves not good, and T-CHOL and low-density lipoprotein but obviously increase. And another research finds that excellent think of is bright can not fallLow T-CHOL, and after treatment, leptin and hs-CRP significantly raise, and this means the bright increase heart of excellent think of diseaseSick risk. Melbine is a kind of insulin sensitizer, is mainly used in treating the disease such as insulin resistance or metabolic syndromeDisease, an investigation demonstration, the use of melbine increases year by year in Young Female, and PCOS is mainly formerCause, but one researched and proposed melbine and be not suitable for treating PCOS in puberty, and once drug withdrawal, all off-notes are repeatedly.In addition, studies show that and adopt contraceptive, low dosage Flutamide associating melbine to intervene PCOS12 week in puberty, find to controlAfter treating, the scoring of patient's forearm grip obviously declines, and stomach fat is without obvious change, and in article, the reduction of grip means lengthThe anti-male treatment of phase affects the development of Pubertal girls bone. Puberty, growth and development stage, can not accept the long-term of Western medicineTreatment, the medicine treatment of therefore finding other effective and safes is necessary.
Summary of the invention
Based on above weak point, the invention provides a kind of Chinese medicine compound prescription for the treatment of Polycystic Ovary Syndrome in Adolescence.
The technology used in the present invention is as follows: a kind of Chinese medicine compound prescription for the treatment of Polycystic Ovary Syndrome in Adolescence, formula is by heavyAmount umber proportioning, contains Radix Astragali 30-35 part, American Ginseng 20-25 part, red sage root 15-20 part, hawthorn 15-20 part, FuSiberian cocklebur 15-20 part, bighead atractylodes rhizome 20-25 part and dried orange peel 15-20 part.
Another object of the present invention is to provide the use of Chinese medicine compound prescription as above in treatment Polycystic Ovary Syndrome in AdolescenceOn the way.
The present invention adopts air making-up and spleen enlivening, PCOS in puberty is treated in the ruling by law of the dehumidifying of reducing phlegm, promoting blood circulation for regulating menstruation, with other traditional Chinese medicine researchesCompare, this Chinese medicine compound prescription can not only reduce lutropin in patients serum (LH), lutropin/follicular stimulating hormone(LH/FSH), total testosterone (T), androstenedione (AND) level, can also reduce cholesterol in blood fat (TC), carry fatThe level of protein B (APOB), adjusts the menstrual cycle thereby reach, and improves excessive androgen mass formed by blood stasis, correcting lipid disorderObject.
Compatibility foundation of the present invention:
This Chinese medicine compound prescription is made up of the Radix Astragali, American Ginseng, the red sage root, hawthorn, Poria cocos, the bighead atractylodes rhizome, dried orange peel, play altogether air making-up and spleen enlivening,The reduce phlegm merit of dehumidifying, promoting blood circulation for regulating menstruation. In side, the Radix Astragali has the merit of tonifying Qi, sharp water; American Ginseng boosting qi and nourishing yin promotes the production of body fluid. In weAmerican Ginseng, the Radix Astragali enter taste, the sweet temperature of property, and the gas of main tonifying spleen, is monarch drug in a prescription. American Ginseng, Radix Astragali invigorating the spleen, spleen be the day after tomorrow itThis, the strong fortune of temper, can help spleen to reduce phlegm wet, helps the capable hemostasis of gas; While spleen rises stomach and falls, and edema with the liver involved must be supported, and important department gets profit, gasBlood is in harmonious proportion, and eliminates the source of phlegm stasis of blood regeneration, and tonifying Qi and blood biochemistry originally. On the other hand, American Ginseng, Radix Astragali invigorating the spleen, qi and bloodThe source of vital function abundance, will nourish first angel's kidney essense abundance the day after tomorrow, and menstrual function is normal. Minister is with the bighead atractylodes rhizome, both helped American Ginseng,Radix Astragali invigoration spleen qi is more drying damp and strengthening spleen with the property of bitter temperature; And minister is with the red sage root, hawthorn nourshing blood and promoting blood circulation, makes qi and blood fill Sheng, gasAlong blood and, phlegm is without the source of regeneration, passages through which vital energy circulates advances freely, the merit that reinforcement activating blood and promoting diuresis reduces phlegm. The spleen being in charge of dampness, weakness of the spleen and the stomach,Transporting is unable, and phlegm is wet to be stagnated, and Gu Zuo, with Poria cocos, dried orange peel, joins bighead atractylodes rhizome invigorating the spleen gas, can eliminating phlegm wet again.
Detailed description of the invention
The present invention will be further described for example below:
Embodiment 1
Treat a Chinese medicine compound prescription for Polycystic Ovary Syndrome in Adolescence, the proportioning by weight of filling a prescription, contain 35 parts of the Radixs Astragali,20 parts of 25 parts of American Ginsengs, 20 parts of the reds sage root, 20 parts of hawthorn, 20 parts, Poria cocos, 25 parts of the bighead atractylodes rhizomes and dried orange peels.
The formulation of this compound is granule and decoction;
Usage and consumption: granule, 1 pair of mixing in water for oral taking, sooner or later respectively once, one month is a course for the treatment of; Decoction, 1 pair is decocted in water for oral dose,Sooner or later it within one month, is respectively once, a course for the treatment of;
Take grams: 130g/ days;
45 example PCOS in puberty are carried out to Chinese medicine compound prescription intervention: patients serum LH, LH/FSH, T, AND level are controlledBefore treating, obviously reduce, there is statistical significance (P < 0.05); After treatment, patient's serum TC, APOB level are treated front brightAobvious reduction, has statistical significance (P < 0.05), finds to have no adverse reaction.
Embodiment 2
Treat a Chinese medicine compound prescription for Polycystic Ovary Syndrome in Adolescence, the proportioning by weight of filling a prescription, 30 parts of the Radixs Astragali, west20 parts of American ginsengs, 15 parts of the reds sage root, 15 parts of hawthorn, 15 parts, Poria cocos, 20 parts of the bighead atractylodes rhizomes, 15 parts of dried orange peels.
The formulation of this compound is granule and decoction;
Usage and consumption: granule, 1 pair of mixing in water for oral taking, sooner or later respectively once, one month is a course for the treatment of; Decoction, 1 pair is decocted in water for oral dose,Sooner or later it within one month, is respectively once, a course for the treatment of;
Take grams: 130g/ days;
45 example PCOS in puberty are carried out to Chinese medicine compound prescription to be intervened three months: patients serum LH, LH/FSH, T, AND waterBefore flat treatment, obviously reduce, there is statistical significance (P < 0.05); After treatment, patient's serum TC, APOB level are controlledBefore treating, obviously reduce, there is statistical significance (P < 0.05), find to have no adverse reaction.
Embodiment 3
Acute toxicity testing data
Test unit: Heilongjiang University of Chinese Medicine
Test commencement date and deadline: 2015.11.～2015.12
The preservation place of firsthand information: Heilongjiang University of Chinese Medicine experimental center
Compound preparation maximum dosage-feeding is measured
Object: observing the issuable toxic reaction of compound preparation gastric infusion, is reference data for clinical drug use foundation.Content: compound preparation is with Cmax 1.86g/ml, and maximum volume 0.4ml/10g, carries out secondary gastric infusion not to mouseMeasure LD50. So, do maximum dosage-feeding and measure: with Cmax 1.86g/ml, maximum volume 0.4ml/10g, secondaryGastric infusion.
Conclusion: mouse oral administration maximum dosage-feeding is 74.4g/kg, 173.6 times of quite clinical adult's consumption, clinical oral administration is usedMedicine is quite safe.
Experiment material
1. medicine: compound preparation provides medicine by hospital, lot number: 20151001
Specification: every bottled 10ml, concentration is 1g/ml, clinical is oral medication, is grown up each 1 bottle, 3 times on the one.
2. animal:
Small white mouse is Kunming kind, female, between body weight 18～22g, numerous by Heilongjiang University of Chinese Medicine's Experimental Animal CenterGrow and provide. The quality certification is SCXK (black) 2008004; Issuing unit is Science and Technology Department of Heilongjiang Province.
Experimental technique:
Get 20 of 18-22g Healthy female small white mouses, it is 1.86g/ml that every mouse gavages compound preparation concentration by 0.4ml/10gLiquid (having reached maximum administration volume, maximum administration concentration), in one day, gavage continuously twice, be 6 hours interval time,Mouse active situation and dead quantity in Continuous Observation 7 days.
Experimental result
Table 1 compound preparation acute toxicity testing observed result
Table 2 compound preparation mouse maximum dosage-feeding measurement result
Mouse maximum dosage-feeding, tolerance times number calculating method:
Experiment conclusion
Because this medicine is not measured LD50, according to the requirement of new Chinese medicine examination & approval, carry out the mensuration of maximum dosage-feeding. Result is littleMouse is as stated above after oral administration, and in 7 days, none example is dead, and freely, diet is normal in activity, and hair is glossy, without just rareDeng. The maximum dosage-feeding of compound preparation mouse oral administration is 74.4g/kg as calculated, is equivalent to 173.6 of clinical adult's consumptionDoubly, therefore think, this medicine clinical oral administration medication is quite safe.
Embodiment 4
Polycystic Ovary Syndrome in Adolescence (polycysticovarysyndrome, PCOS) is gynaecology's endocrine stubborn problem,Taking oligomenorrhea, amenorrhoea, crinosity, obesity etc. as main clinical characteristics. This disease pathogenesis is not yet illustrated so far. It is controlledTreatment is mainly life style adjustment, symptomatic treatment and control Abnormality of Glycolipid Metabolism, and conventional medicine is melbine and oralContraceptive, but puberty PCOS patient in the Development in Puberty stage, lose weight too fast can affect normal growth growth,And its many places are in junior middle school or senior high school period, and learning pressure is larger, can not ensure keep on a diet fully and increase motionTime to be to lose weight, in addition the concrete medicine for treatment time of melbine and oral contraceptive not yet clear and definite, and drug withdrawalEasily repeatedly, treatment by Chinese herbs PCOS in puberty has obtained certain effect to rear disease at present, and bad reaction is less. ThisResearch adopts compound of Chinese herbal medicine PCOS40 in puberty example, and curative effect is obvious, and existing report is as follows.
1 data and method
1.1 research objects: 40 routine patients all derive from Heilongjiang University of Chinese Medicine attached in year October in December, 2012 to 2015The PCOS in puberty of one hospital-based outpatient obstetrical clinic. Patient age distribution 12-18 year, year mean age (17.05 ± 0.33).
1.2 diagnostic criteria diagnostic criteria:
1. menarche is more than 2 years, oligomenorrhea, amenorrhoea;
2. clinical or biochemical excessive androgen mass formed by blood stasis;
3. the ultrasonic prompting Ovarian Volume of pelvic cavity > 10cm3, and (or) little ovarian follicle >=12 of a side or bilateral ovaries diameter 2-9mm,Wherein Ovarian Volume > 10cm3Must condition. Get rid of the disease that other cause that androgen increases, as Cushing syndrome, elder generationNature congenital adrenal hyperplasia and produce androgenic tumour, meeting above-mentioned three diagnostic criteria diagnosable is PCOS in puberty.
1.3. inclusive criteria
1. meet PCOS diagnostic criteria in puberty;
2. age 12-18 one full year of life
1.4. exclusion standard
1. in nearly 3 months, take the medicine that affects this experimental result;
2. suffer from serious body or psychosis person;
3. patient does not take medicine in accordance with regulations, cannot judge curative effect person.
1.5 methods for the treatment of
Chinese native medicine compound prescription pellet agent treatment three months, usage and consumption: granule, 1 pair of mixing in water for oral taking, sooner or later respectively once, one month isA course for the treatment of;
Take grams: 130g/ days;
1.6 observation indexs: ordinary circumstance: gather patient's age, height, body weight, waistline, hip circumference, calculate BMI, waist sternRatio; Carry out the inspections such as crinosity scoring, black sour jujube skin, acne, the fat incidence of overflowing; Observe menstruation; Biochemical indicator: suffer fromPerson is in 3-5 days survey serum lutropin (luteinizing of natural menstrual cycle or progestational hormone withdrawal bleedingHormone, LH), follicular stimulating hormone (folliclestimulatinghormone, FSH), testosterone (testosterone, T), sulphurAcid dehydrobenzene (dehydroepiandrosteronesulfate, DHEAS), androstenedione (androstenedione, AND),Sex hormone binding globulin (sexhormonebindingglobulin, SHBG), calculates LH/FSH; Fasting blood-glucose (fastingPlasmaglucose, FPG), 2h blood sugar level, FPI (fastinginsulin, FINS), 2h insulin level,T-CHOL (cholesteroltotal, TC), triglycerides (triglyceride, TG), HDL (highdensityLipoprotein, HDL), low-density lipoprotein (lowdensitylipoprotein, LDL), aPoA (APOA), carry fatProtein B (APOB), lipoprotein (LPA), calculate HOMA-IR, APOB/APOA.
1.7 statistical analysis statistical methods, adopt SPSS17.0 statistical software to analyze, if measurement data is normal distribution,Represent with x ± s, adopt paired t-test; If be not normal distribution, represent with median (range interquartile), carry outRank test. The relatively employing x of frequency2Inspection. P < 0.05 has statistical significance for difference.
2. result
Before and after 2.1 treatments 3 months, after the relatively treatment of Clinical symptoms, 61% patient's menstrual cycle recovered normal; Patient's hip circumferenceBefore treatment, obviously lower, there is statistical significance (P < 0.05); BMI, waistline, hip circumference, the waist for the treatment of Patients Before And AfterStern ratio, crinosity scoring, acne incidence, black sour jujube skin and excessive fat situation are without significant change (P > 0.05). In table 3.
Clinical symptoms comparison before and after table 3 treatment
Patient's serum Lh after the relatively treatment of reproductive hormone indices before and after 2.2 treatments 3 months, LH/FSH, T, AND,Level is treated front obvious reduction, has statistical significance (P < 0.05); FSH, DHEAS, SHBG before and after treatmentEqual no significant difference (P > 0.05). In table 4.
Table 4 is treated the comparison of three months front and back reproductive hormone indices
3 months endocrine metabolisms before and after 2.3 treatments
After treatment, patient's serum TC, APOB level are treated front obvious reduction, have statistical significance (P < 0.05); TreatmentBefore and after fasting blood glucose level, 120 minutes glucose levels, FPI level, 2h insulin level, IR, TG,HDL, LDL, APOB/APOA, the equal no significant difference of lipoprotein, not statistically significant (P > 0.05). In table 5.Table 5 is treated the comparison of three months front and back glycolipid metabolism indices
Claims (2)
1. treat the Chinese medicine compound prescription of Polycystic Ovary Syndrome in Adolescence for one kind, it is characterized in that, the proportioning by weight of filling a prescription, contains Radix Astragali 30-35 part, American Ginseng 20-25 part, red sage root 15-20 part, hawthorn 15-20 part, Poria cocos 15-20 part, bighead atractylodes rhizome 20-25 part and dried orange peel 15-20 part.
2. a Chinese medicine compound prescription as claimed in claim 1 is in the purposes for the treatment of in Polycystic Ovary Syndrome in Adolescence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610005069.2A CN105596495B (en) | 2016-01-06 | 2016-01-06 | The Chinese medicine compound prescription for treating Polycystic Ovary Syndrome in Adolescence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610005069.2A CN105596495B (en) | 2016-01-06 | 2016-01-06 | The Chinese medicine compound prescription for treating Polycystic Ovary Syndrome in Adolescence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105596495A true CN105596495A (en) | 2016-05-25 |
| CN105596495B CN105596495B (en) | 2019-11-05 |
Family
ID=55977225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610005069.2A Active CN105596495B (en) | 2016-01-06 | 2016-01-06 | The Chinese medicine compound prescription for treating Polycystic Ovary Syndrome in Adolescence |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105596495B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108653434A (en) * | 2018-07-11 | 2018-10-16 | 贾丽妍 | A kind of pharmaceutical composition for treating spleen emptiness and wet sputum type Stein-Leventhal syndrome |
| CN109224054A (en) * | 2018-11-28 | 2019-01-18 | 辽宁中医药大学 | A kind of Chinese medicine composition and preparation method thereof for endomorphy type PCOS point-application |
| CN109420087A (en) * | 2017-08-25 | 2019-03-05 | 王停 | A kind of Chinese medicinal formulae for the conditioning of fire derived from stagnation of liver-QI type Stein-Leventhal syndrome |
| CN113599475A (en) * | 2021-09-07 | 2021-11-05 | 宁夏医科大学 | Middle-warming and kidney-tonifying composition for treating polycystic ovarian syndrome and preparation method and application thereof |
| CN114306534A (en) * | 2021-11-17 | 2022-04-12 | 北京斯利安健康科技有限公司 | Composition for treating polycystic ovarian syndrome, preparation method and application |
-
2016
- 2016-01-06 CN CN201610005069.2A patent/CN105596495B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 王春华等: "《月经病偏验方与食疗》", 30 September 2015, 金盾出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109420087A (en) * | 2017-08-25 | 2019-03-05 | 王停 | A kind of Chinese medicinal formulae for the conditioning of fire derived from stagnation of liver-QI type Stein-Leventhal syndrome |
| CN108653434A (en) * | 2018-07-11 | 2018-10-16 | 贾丽妍 | A kind of pharmaceutical composition for treating spleen emptiness and wet sputum type Stein-Leventhal syndrome |
| CN109224054A (en) * | 2018-11-28 | 2019-01-18 | 辽宁中医药大学 | A kind of Chinese medicine composition and preparation method thereof for endomorphy type PCOS point-application |
| CN109224054B (en) * | 2018-11-28 | 2021-08-13 | 辽宁中医药大学 | Traditional Chinese medicine composition for acupoint application of obese PCOS and preparation method thereof |
| CN113599475A (en) * | 2021-09-07 | 2021-11-05 | 宁夏医科大学 | Middle-warming and kidney-tonifying composition for treating polycystic ovarian syndrome and preparation method and application thereof |
| CN114306534A (en) * | 2021-11-17 | 2022-04-12 | 北京斯利安健康科技有限公司 | Composition for treating polycystic ovarian syndrome, preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105596495B (en) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105596495A (en) | Chinese herbal compound for treating pubertal polycystic ovary syndrome | |
| CN102613555A (en) | Maca powder and ginseng composition and preparation method thereof | |
| CN103830577A (en) | Medicine composition for treating liver and gall calculus and kidney stone and application thereof | |
| CN109528980A (en) | A kind of Chinese medicine composition and its pharmacy application for treating Ovary reserve decline disease | |
| CN102302659B (en) | Chinese medicinal composition for kidney-yang deficiency and phlegm-retention type polycystic ovanian syndrome | |
| CN102755600B (en) | Traditional Chinese medicine compound for resisting breast cancer metastasis and reoccurrence, preparation method and uses | |
| CN105327069A (en) | Formulation, preparation method and application of liver soothing traditional Chinese herbal medicine composition | |
| CN100444886C (en) | A Chinese medicine for treating threatened abortion | |
| CN107982331A (en) | A kind of Chinese medicine preparation essential oil of the external curing proliferation of mammary gland | |
| CN102908517A (en) | Chinese medicine composition for curing oligospermia and asthenozoospermia and preparation method of Chinese medicine composition | |
| CN105582274A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparing method thereof | |
| CN103479783A (en) | Chinese medicine composite for curing climacteric melancholia and application thereof | |
| CN109276685A (en) | The Chinese medicine composition and preparation method thereof of preventing/treating prostate class disease | |
| CN101669984A (en) | Anti-fatigue immuno-regulation Chinese medicinal product | |
| Yu et al. | Sports and Chinese herbal medicine | |
| CN108635483A (en) | A kind of Chinese medicinal formulae for treating hypoovarianism | |
| CN101422547A (en) | Traditional Chinese medicine for treating kidney-deficiency blood-insufficiency type amenorrhea | |
| CN104027533B (en) | Traditional Chinese medicine composition for treating polycystic ovary syndrome of kidney deficiency and phlegm stagnation type with insulin resistance and an application thereof | |
| CN104042881B (en) | For regulating the compositions of ovarian function | |
| CN103585583A (en) | Traditional Chinese medicine composition for treating hepatic calculus and application thereof | |
| CN103230518A (en) | Traditional Chinese medical composition for treating peptic ulcer | |
| Ramaswamy | Ayurveda-An ancient healing system’s gifts to the modern woman | |
| CN105362372A (en) | Traditional Chinese medicine for treating primary PCI (percutaneous coronary intervention) postoperative poor myocardial perfusion of patients suffering from heart-qi deficiency type ST-segment elevation myocardial infarction | |
| CN105902600A (en) | Yaotongling wine and preparation method thereof | |
| CN104771653A (en) | Traditional Chinese medicine preparation for treating oligospermia/asthenozoospermia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |